Exploratory clinical study on the smartphone application for type 2 diabetes
Completed
- Conditions
- Type 2 diabetes
- Registration Number
- jRCT1030220061
- Lead Sponsor
- Terumo Corporation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
All of the following criteria must be met in order to participate in this study.
- Patients who are visiting "Okamoto Clinic" or "Tomonaga Clinic" or "Mirai Clinic" ("the trial institutions") and who have obtained written informed consent.
- Patients aged 20 to 65 years at the time of obtaining consent.
- Patients scheduled to visit the trial institutions once a month.
- Patients who, at the time of obtaining consent, have been diagnosed with type 2 diabetes for at least 12 weeks.
- Patients with HbA1c value of 7.0% to 9.0% or less at the time of obtaining consent. (If HbA1c at the time of obtaining consent is not available, it is permitted to use HbA1c within 3 months from the time of obtaining consent.)
- Patients who own iPhone and have been using it continuously for 12 weeks or more. (It is deemed that patients are using iPhone continuously, if they use it more than 4 days a week.)
- Patients deemed by the investigator to be able to use the diabetes management program DRM01 ("the app").
Exclusion Criteria
Subjects were excluded based on 16 criteria:
- Type 1 diabetes.
- Secondary diabetes.
- Patients receiving or planning to start intensive insulin therapy.
- Patients with renal impairment. (eGFR less than 45 mL/min/1.73m2 or urinary microalbumin more than 300 mg/gCre)
- Patients undergoing or planning to start hemodialysis.
- Patients who have been diagnosed with dementia or are being treated for dementia.
- Patients with experience requiring third-party intervention to treat hypoglycemia.
- Patients with or need to have any exercise or dietary restrictions due to diseases other than diabetes.
- Patients who have liver or cardiovascular diseases and are judged by the doctor to be difficult to participate in this study.
- Patients with malignant tumors.
- Patients with serious infections.
- Patients who are dependent on alcohol or drugs, or have unstable psychiatric disorders and are deemed by the investigator to be inappropriate for this study.
- Patients scheduled to be hospitalized or undergo surgery during the study period.
- Patients who are pregnant, may be pregnant, or wish to be pregnant. (women only)
- Patients who participated in other clinical trials in the 4 weeks prior to the consent of this study.
- Patients deemed by the investigator to be inappropriate for this study.
Study & Design
- Study Type
- Interventional
- Study Design
- single assignment
- Primary Outcome Measures
Name Time Method - Application usage rate and usage rate by recorded item
- Secondary Outcome Measures
Name Time Method